Ocular hypertension
Ocular hypertension is a special phenomenon that has been gradually recognized through decades of clinical practice in the diagnosis and treatment of primary open-angle glaucoma. In clinical work, people have also continuously confirmed that the vast majority of patients with glaucoma who have been diagnosed clearly have the common feature of increased intraocular pressure. Although ocular hypertension develops slowly and rarely causes damage to the optic disc and visual field, it does share an important pathological factor with open-angle glaucoma, namely increased intraocular pressure.
-
Site of disease:
Eye -
Infectious :
Not contagious -
Frequent population:
All groups -
Related symptoms:
Retinal hemorrhage high intraocular pressure visual impairment glaucoma spots myopia arc -
Concurrent disease:
Related Drugs
AZOPT- brinzolamide_suspension/ drops
Indication: AZOPT is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. AZOPT is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
Manufacturer:
Novartis Pharmaceuticals Corporation
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC- dorzolamide hydrochloride and timolol maleate_solution/ drops
Indication: Dorzolamide hydrochloride and timolol maleate ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of dorzolamide hydrochloride and timolol maleate ophthalmic solution administered twice a day was slightly less than that seen with the concomitant administration of 0. 5% timolol administered twice a day and 2% dorzolamide administered three times a day [see Clinical Studies (14) Dorzolamide hydrochloride and timolol maleate ophthalmic solution is a combination of dorzolamide hydrochloride, a carbonic anhydrase inhibitor, and timolol maleate, a beta adrenergic receptor blocking agent, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. The IOP-lowering of dorzolamide hydrochloride and timolol maleate ophthalmic solution twice daily was slightly less than that seen with the concomitant administration of 0. 5% timolol twice daily, and 2% dorzolamide three times daily.
Manufacturer:
A-S Medication Solutions